Financial Ratios Charles River Laboratories International, Inc.
Equities
CRL
US1598641074
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 156.03 USD | +2.36% |
|
-4.19% | -21.78% |
| 05-13 | Charles River Laboratories, Medipost Sign MoU on GMP-Compliant Testing | MT |
| 05-13 | Charles River Laboratories and Medipost sign non-exclusive MoU to advance GMP testing solutions | RE |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 6.34 | 5.63 | 5.19 | 4.34 | 4.24 | |||||
Return on Total Capital | 8.05 | 7.03 | 6.33 | 5.22 | 5.13 | |||||
Return On Equity % | 16.84 | 17.54 | 14.38 | 0.71 | -4.23 | |||||
Return on Common Equity | 16.82 | 17.65 | 14.44 | 0.29 | -4.36 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 37.78 | 36.79 | 37.03 | 34.76 | 34.98 | |||||
SG&A Margin | 16.33 | 16.54 | 17.81 | 17.87 | 18.13 | |||||
EBITDA Margin % | 25.42 | 24.2 | 23.5 | 21.49 | 21.83 | |||||
EBITA Margin % | 21.45 | 20.25 | 19.22 | 16.66 | 16.86 | |||||
EBIT Margin % | 17.92 | 16.56 | 15.89 | 13.48 | 12.4 | |||||
Income From Continuing Operations Margin % | 11.27 | 12.39 | 11.63 | 0.62 | -3.54 | |||||
Net Income Margin % | 11.04 | 12.23 | 11.49 | 0.55 | -3.59 | |||||
Net Avail. For Common Margin % | 11.04 | 12.23 | 11.49 | 0.25 | -3.59 | |||||
Normalized Net Income Margin | 8.68 | 7.83 | 7.82 | 6.36 | 5.77 | |||||
Levered Free Cash Flow Margin | 17.81 | 7.53 | 5.3 | 12.09 | 14.25 | |||||
Unlevered Free Cash Flow Margin | 19.12 | 8.46 | 7.37 | 14.04 | 15.92 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.57 | 0.54 | 0.52 | 0.52 | 0.55 | |||||
Fixed Assets Turnover | 2.45 | 2.31 | 2.12 | 2 | 1.99 | |||||
Receivables Turnover (Average Receivables) | 5.62 | 5.7 | 5.39 | 5.4 | 5.62 | |||||
Inventory Turnover (Average Inventory) | 11.45 | 11.05 | 8.18 | 8.02 | 9.04 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.23 | 1.32 | 1.52 | 1.41 | 1.29 | |||||
Quick Ratio | 0.86 | 0.9 | 1 | 0.92 | 0.82 | |||||
Operating Cash Flow to Current Liabilities | 0.74 | 0.57 | 0.65 | 0.74 | 0.66 | |||||
Days Sales Outstanding (Average Receivables) | 64.81 | 65.09 | 67.56 | 67.47 | 64.81 | |||||
Days Outstanding Inventory (Average Inventory) | 31.8 | 33.58 | 44.52 | 45.38 | 40.27 | |||||
Average Days Payable Outstanding | 26.33 | 29.16 | 25.04 | 22.16 | 20 | |||||
Cash Conversion Cycle (Average Days) | 70.28 | 69.51 | 87.04 | 90.69 | 85.08 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 113.91 | 104.1 | 85.46 | 79.28 | 81.95 | |||||
Total Debt / Total Capital | 53.25 | 51 | 46.08 | 44.22 | 45.04 | |||||
LT Debt/Equity | 112.52 | 102.44 | 83.8 | 77.65 | 80.05 | |||||
Long-Term Debt / Total Capital | 52.6 | 50.19 | 45.19 | 43.31 | 43.99 | |||||
Total Liabilities / Total Assets | 63.1 | 60.23 | 55.35 | 53.4 | 55 | |||||
EBIT / Interest Expense | 8.58 | 11.11 | 4.8 | 4.32 | 4.65 | |||||
EBITDA / Interest Expense | 12.86 | 17.49 | 7.75 | 7.7 | 9.21 | |||||
(EBITDA - Capex) / Interest Expense | 9.77 | 12.01 | 5.42 | 5.86 | 7.17 | |||||
Total Debt / EBITDA | 3.11 | 3.03 | 2.95 | 2.86 | 2.67 | |||||
Net Debt / EBITDA | 2.85 | 2.81 | 2.69 | 2.66 | 2.45 | |||||
Total Debt / (EBITDA - Capex) | 4.09 | 4.42 | 4.22 | 3.76 | 3.43 | |||||
Net Debt / (EBITDA - Capex) | 3.75 | 4.09 | 3.85 | 3.5 | 3.15 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 21.08 | 12.31 | 3.86 | -1.92 | -0.85 | |||||
Gross Profit, 1 Yr. Growth % | 23.96 | 9.59 | 4.19 | -7.93 | -0.23 | |||||
EBITDA, 1 Yr. Growth % | 30.3 | 7.76 | -0.01 | -9.88 | 0.7 | |||||
EBITA, 1 Yr. Growth % | 33.76 | 7.01 | -2.39 | -14.48 | 0.28 | |||||
EBIT, 1 Yr. Growth % | 39.19 | 4.94 | -1.55 | -16.25 | -8.81 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 9.18 | 23.51 | -2.48 | -94.74 | -662.11 | |||||
Net Income, 1 Yr. Growth % | 7.32 | 24.36 | -2.39 | -95.32 | -750.08 | |||||
Normalized Net Income, 1 Yr. Growth % | 1.84 | 2.8 | 2.09 | -19.51 | -10.11 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 5.56 | 24.74 | -2.74 | -97.83 | -1.56K | |||||
Accounts Receivable, 1 Yr. Growth % | 4.07 | 17.03 | 3.72 | -7.62 | -1.67 | |||||
Inventory, 1 Yr. Growth % | 7.24 | 28.45 | 48.65 | -26.75 | 7.38 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 21.61 | 17.26 | 9.49 | -0.85 | 0.01 | |||||
Total Assets, 1 Yr. Growth % | 27.93 | 8.24 | 7.79 | -8.14 | -5.22 | |||||
Tangible Book Value, 1 Yr. Growth % | 156.81 | -33.06 | -56.3 | -70.04 | -155.65 | |||||
Common Equity, 1 Yr. Growth % | 19.87 | 17.42 | 20.85 | -3.76 | -8.58 | |||||
Cash From Operations, 1 Yr. Growth % | 39.19 | -18.55 | 10.37 | 7.41 | 0.42 | |||||
Capital Expenditures, 1 Yr. Growth % | 37.35 | 41.95 | -1.91 | -26.86 | -5.93 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 125.4 | -52.14 | -28.1 | 126.66 | 16.9 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 102.76 | -49.91 | -10.88 | 88.6 | 12.44 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 16.21 | 16.61 | 8 | 0.93 | -1.39 | |||||
Gross Profit, 2 Yr. CAGR % | 17.73 | 16.72 | 6.93 | -2.06 | -4.16 | |||||
EBITDA, 2 Yr. CAGR % | 23.93 | 19.49 | 3.84 | -5.24 | -4.59 | |||||
EBITA, 2 Yr. CAGR % | 26.12 | 20.88 | 2.24 | -8.84 | -7.22 | |||||
EBIT, 2 Yr. CAGR % | 27.9 | 22.47 | 1.7 | -9.43 | -12.42 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 25.29 | 16.12 | 9.75 | -77.34 | -45.6 | |||||
Net Income, 2 Yr. CAGR % | 24.56 | 15.53 | 10.18 | -78.63 | -44.85 | |||||
Normalized Net Income, 2 Yr. CAGR % | 20.46 | 3.41 | 2.25 | -9.65 | -21.91 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 22.43 | 14.75 | 10.14 | -85.48 | -43.8 | |||||
Accounts Receivable, 2 Yr. CAGR % | 11.83 | 10.36 | 10.18 | -2.11 | -4.69 | |||||
Inventory, 2 Yr. CAGR % | 11.34 | 17.37 | 38.18 | 4.35 | -11.31 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 15.65 | 19.41 | 13.31 | 4.19 | -0.42 | |||||
Total Assets, 2 Yr. CAGR % | 22.34 | 17.67 | 8.01 | -0.49 | -6.69 | |||||
Tangible Book Value, 2 Yr. CAGR % | 44.21 | 31.11 | -45.91 | -63.82 | -59.17 | |||||
Common Equity, 2 Yr. CAGR % | 24.53 | 18.64 | 19.12 | 7.84 | -6.2 | |||||
Cash From Operations, 2 Yr. CAGR % | 25.77 | 6.47 | -5.19 | 8.88 | 3.86 | |||||
Capital Expenditures, 2 Yr. CAGR % | 27.6 | 39.63 | 18 | -15.3 | -17.05 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 31.85 | 5.41 | -41.05 | 26.98 | 63.47 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 29.95 | 1.98 | -32.91 | 29.18 | 46.06 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 16.03 | 14.9 | 12.2 | 4.59 | 0.33 | |||||
Gross Profit, 3 Yr. CAGR % | 16.65 | 14.87 | 12.52 | 1.73 | -1.45 | |||||
EBITDA, 3 Yr. CAGR % | 21.32 | 17.99 | 12.91 | -1.1 | -3.3 | |||||
EBITA, 3 Yr. CAGR % | 23.1 | 19.04 | 12.94 | -3.85 | -5.89 | |||||
EBIT, 3 Yr. CAGR % | 22.84 | 19.3 | 14.33 | -4.89 | -9.23 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 20.63 | 24.7 | 9.56 | -60.12 | -33.92 | |||||
Net Income, 3 Yr. CAGR % | 19.98 | 24.49 | 9.22 | -61.56 | -33.29 | |||||
Normalized Net Income, 3 Yr. CAGR % | 19.57 | 13.72 | 3.51 | -5.85 | -9.8 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 18.3 | 23.2 | 8.59 | -70.26 | -32.53 | |||||
Accounts Receivable, 3 Yr. CAGR % | 10.83 | 13.54 | 8.1 | 3.89 | -1.97 | |||||
Inventory, 3 Yr. CAGR % | 15.91 | 16.77 | 26.99 | 11.83 | 5.35 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 19.3 | 16.19 | 16.01 | 8.38 | 2.78 | |||||
Total Assets, 3 Yr. CAGR % | 22.13 | 17.45 | 14.28 | 2.34 | -2.09 | |||||
Tangible Book Value, 3 Yr. CAGR % | 31.81 | 11.66 | -9.09 | -55.58 | -58.24 | |||||
Common Equity, 3 Yr. CAGR % | 24.38 | 22.11 | 19.37 | 10.94 | 2.07 | |||||
Cash From Operations, 3 Yr. CAGR % | 20.26 | 8.81 | 7.76 | -1.16 | 5.98 | |||||
Capital Expenditures, 3 Yr. CAGR % | 17.77 | 32.21 | 24.12 | 0.61 | -12.29 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 32.64 | -6.21 | -6.7 | -8.04 | 23.53 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 29.72 | -5.68 | -2.02 | -5.6 | 23.34 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 16.06 | 16.44 | 12.75 | 9.09 | 6.55 | |||||
Gross Profit, 5 Yr. CAGR % | 15.24 | 15.17 | 12.66 | 7.85 | 5.52 | |||||
EBITDA, 5 Yr. CAGR % | 17.62 | 16.72 | 14 | 8.24 | 5.4 | |||||
EBITA, 5 Yr. CAGR % | 19.25 | 17.83 | 14.29 | 7.17 | 4.2 | |||||
EBIT, 5 Yr. CAGR % | 18.36 | 16.04 | 13.91 | 7.08 | 2.54 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 20.64 | 31.44 | 16.15 | -36.96 | -17.2 | |||||
Net Income, 5 Yr. CAGR % | 20.36 | 31.56 | 15.96 | -38.48 | -16.9 | |||||
Normalized Net Income, 5 Yr. CAGR % | 13.93 | 10.05 | 12.44 | 4.01 | -4.47 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 18.74 | 30.14 | 14.97 | -47.62 | -16.56 | |||||
Accounts Receivable, 5 Yr. CAGR % | 12.05 | 11.84 | 10.57 | 7 | 2.79 | |||||
Inventory, 5 Yr. CAGR % | 15.75 | 17.35 | 24.35 | 11.63 | 10 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 15.95 | 18.89 | 16.87 | 11.23 | 9.14 | |||||
Total Assets, 5 Yr. CAGR % | 20.97 | 21.01 | 16.27 | 9.91 | 5.38 | |||||
Tangible Book Value, 5 Yr. CAGR % | 29.11 | 44.94 | -7.7 | -28.86 | -34 | |||||
Common Equity, 5 Yr. CAGR % | 24.82 | 23.28 | 22.25 | 16.19 | 8.4 | |||||
Cash From Operations, 5 Yr. CAGR % | 19.3 | 14.4 | 9.35 | 8.84 | 6.18 | |||||
Capital Expenditures, 5 Yr. CAGR % | 32.85 | 31.55 | 17.86 | 10.64 | 5.64 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 19.27 | 8.28 | -4.14 | 6.18 | 16.27 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 19.43 | 8.89 | -0.38 | 7.24 | 14.6 |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















